Amundi Asset Management US’s Ironwood Pharmaceuticals IRWD Stock Holding History

Amundi Asset Management US’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,300	Closed	-$55K	–	1627
2020 Q2	$55K	Hold	5,300	–	–	﹤0.01%	1459
2020 Q1	$53K	Hold	5,300	–	–	﹤0.01%	1469
2019 Q4	$71K	Hold	5,300	–	–	﹤0.01%	1568
2019 Q3	$46K	Hold	5,300	–	–	﹤0.01%	1574
2019 Q2	$58K	Sell	5,300 -1,028	-16%	-$11.5K	﹤0.01%	1599
2019 Q1	$63K	Buy	+6,328	New	+$70.7K	﹤0.01%	1570

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Amundi Asset Management US's IRWD Position: Q3 2020 in Review

Amundi Asset Management US sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2020, closing a stake of 5,300 shares — an estimated $55K sold.

Amundi Asset Management US first reported a position in IRWD in Q1 2019 and held it in 6 quarters. The position peaked at $71K in Q4 2019. 190 funds tracked by Wall St. Rank hold IRWD as of Q3 2020.

Amundi Asset Management US reported no remaining Ironwood Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Amundi Asset Management US sold 5,300 Ironwood Pharmaceuticals shares in Q3 2020, an estimated $55K.
Amundi Asset Management US first reported a position in Ironwood Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Amundi Asset Management US's Ironwood Pharmaceuticals position peaked at $71K in Q4 2019.
190 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2020.

Based on Amundi Asset Management US's 13F filing for Q3 2020, filed 16 Nov 2020.